Corvus Pharmaceuticals
CRVS
62 hedge funds and large institutions have $66.7M invested in Corvus Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 16 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
2% more funds holding
Funds holding: 61 → 62 (+1)
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
3% more call options, than puts
Call options by funds: $552K | Put options by funds: $536K
6.97% less ownership
Funds ownership: 66.43% → 59.46% (-7%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
51% less capital invested
Capital invested by funds: $136M → $66.7M (-$69.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$9.04M |
| 2 |
Two Sigma Investments
New York
|
+$3.06M |
| 3 |
Two Sigma Advisers
New York
|
+$2.96M |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$2.05M |
| 5 |
Renaissance Technologies
New York
|
+$1.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$12.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$10.1M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.51M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.07M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$968K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Wells Fargo
San Francisco,
California
| – | -$1K | -182 | Closed |
|
CRVS Hedge Fund Activity: Q4 2021 in Review
62 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q4 2021, worth a combined $66.7M — down 51% from $136M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CRVS positions and 16 closed out — a net gain of 1 holder — while 20 added to existing stakes and 12 trimmed.
The largest buyer was Millennium Management, adding an estimated $9.04M. The largest seller was VR Adviser, cutting an estimated $12.3M.
- 62 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q4 2021, up from 61 in Q3 2021.
- Funds reported $66.7M of Corvus Pharmaceuticals stock for Q4 2021, down 51% quarter-over-quarter.
- 17 funds opened new Corvus Pharmaceuticals positions in Q4 2021 and 16 closed out, a net change of +1 holder.
- The largest Corvus Pharmaceuticals buyer in Q4 2021 was Millennium Management, an estimated $9.04M added.
- The largest Corvus Pharmaceuticals seller in Q4 2021 was VR Adviser, an estimated $12.3M sold.
Based on aggregated 13F filings for Q4 2021.